Liquid oxygen vs ambient air during a 6-minute walk in people with pulmonary vascular disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial uses a randomized cross-over design to compare two 6-minute walk distance (6MWD) tests in participants with precapillary pulmonary hypertension who reside in Switzerland. Each participant performs the 6MWD once with ambient air and once with nasal liquid oxygen therapy (~4 L/min), in random order. The primary objective is to see if 6MWD with liquid oxygen is worse than the 6MWD with ambient air. Eligibility includes adults with PAH or CTEPH and related conditions, stable therapy, and prior desaturation during exercise. Exclusions include severe hypoxemia and any condition that would prevent safe participation in the procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Minimum 18 years of age
* Written informed consent
* Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease
* Former desaturation under exercise defined as SpO2-decrease \>3%
* Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)

Exclusion Criteria:

* Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \< 6.9 kPa
* Inability or contraindications to undergo the investigated intervention
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.

Where it's running

• University Hospital Zurich
  Zurich, Canton of Zurich, Switzerland Recruiting

Study contacts

• Principal investigator: Silvia Ulrich, Prof. Dr. med. — University Hospital Zurich, Department of Pulmonology
• Study coordinator: Silvia Ulrich, Prof. Dr. med.
• Email: silvia.ulrich@usz.ch
• Phone: +41442552220

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of ambient air vs nasal liquid oxygen on exercise performance in pulmonary vascular disease

  This study tests whether using nasal liquid oxygen during a 6-minute walk test changes how far patients with PAH or CTEPH can walk compared to breathing room air.

  Recruiting University of Zurich · Zurich, Canton of Zurich · NCT07777445

• Vasoactive Agents in Pulmonary Hypertension Crisis

  This trial tests whether dopamine, norepinephrine, or epinephrine can safely and effectively help people with a pulmonary hypertension crisis who are in the hospital.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality and 2 other locations · NCT07667829

• Levosimendan to see if it helps the heart after PEA in CTEPH

  This small randomized trial tests whether giving levosimendan around surgery helps reduce pulmonary artery pressure and support right heart function after pulmonary endarterectomy for CTEPH.

  Recruiting Meshalkin Research Institute of Pathology of Circulation · Novosibirsk · NCT07914933

• Sleep problems in PAH patients: how sleep breathing relates to PAH outcomes

  This study tests how sleep-disordered breathing and nocturnal oxygen changes relate to outcomes in adults with pulmonary arterial hypertension.

  Recruiting Chinese Pulmonary Vascular Disease Research Group · Beijing · NCT07852403

• Treprostinil inhalation powder for PAH patients switching from selexipag

  This study tests whether inhaled treprostinil (LIQ861) is safe and tolerable for adults with PAH who are moving from oral selexipag to inhaled therapy.

  Recruiting Phase 4 Liquidia Technologies, Inc. · Columbus, Georgia · NCT07759804

• Escalation options for PAH patients already on dual therapy

  This trial tests whether adding a prostacyclin pathway drug or increasing sildenafil dose helps PAH patients at intermediate-to-high risk who aren’t at low risk despite dual therapy.

  Recruiting Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT07713914

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.